Skip to main content
Inify Laboratories AB logo

Inify Laboratories AB — Investor Relations & Filings

Ticker · INIFY ISIN · SE0017486103 LEI · 549300306YYJ3BX3VB98 ST Human health and social work activities
Open in API
Filings indexed 333 across all filing types
Latest filing 2026-04-29 Interim / Quarterly Rep…
Country SE Sweden
Listing ST INIFY

About Inify Laboratories AB

https://www.inify.com/

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. The company utilizes a fully digital, standardized, and AI-supported workflow for histopathology analysis. This integrated service model is designed to optimize the entire diagnostic process, from sample receipt to final report, ensuring high quality and significantly reduced turnaround times for clinical partners. Initially focused on prostate cancer, the company has expanded its diagnostic capabilities to include other areas such as gastroenterology. By streamlining the clinical pathway, Inify Laboratories enables healthcare providers to receive faster results, which facilitates earlier patient follow-up and treatment planning.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 89% confidence The document is titled “Kvartalsrapport första kvartalet 2026” and contains detailed quarterly financial information including net sales, EBITDA, cash flow, financial position, segment commentary, balance sheet items (tangible and intangible assets, inventories, leasing, employees), MD&A–style narrative and outlook. This is a full interim/quarterly report rather than a brief earnings release or a notice of publication. Therefore, it should be classified as an Interim/Quarterly Report (IR). Q1 2026
2026-04-29 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 99% confidence The document is titled “Interim report for the first quarter 2026” and contains substantive financial statements and analysis for the first quarter (e.g., net sales, EBITDA, cash at period end, detailed sections on financial development, operating results, cash flow, tangible and intangible assets, inventories, leases, employees). It is clearly a comprehensive interim/quarterly report rather than an announcement or summary. Therefore, it matches the Interim / Quarterly Report category. Q1 2026
2026-04-29 English
Inify Laboratories har tecknat avtal med Region Jämtland Härjedalen för prostatacancerdiagnostik
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing that Inify Laboratories has signed a service agreement with Region Jämtland Härjedalen for prostate cancer diagnostics. It contains no financial results, no management or board changes, no share issues, no dividends, no M&A activity, and does not present an annual or interim report. It also is not announcing the publication of another report. As a general public market announcement that does not fit any more specific category, it falls under Regulatory Filings (RNS).
2026-04-24 Swedish
Inify Laboratories has signed an agreement with Region Jämtland Härjedalen for prostate cancer diagnostics
Regulatory Filings Classification · 85% confidence The document is a press release regarding Inify Laboratories entering into a service agreement with Region Jämtland Härjedalen for prostate cancer diagnostics. It is published as a stock exchange announcement under EU Market Abuse Regulation (MAR) article 17, providing ‘inside information’. It does not contain earnings data, board changes, financial results, or formal report publication. It falls into the catch-all category for miscellaneous regulatory announcements – Regulatory Filings (RNS).
2026-04-24 English
Inify Laboratories has signed an agreement with Region Jämtland Härjedalen for prostate cancer diagnostics - Attachment: Inify_Agreement_signed_with_Region_Jamtland_Harjedalen.pdf
Regulatory Filings Classification · 83% confidence The document is a corporate stock exchange announcement about signing an agreement for prostate cancer diagnostics services. It is not a financial report, earnings release, management change, or other specific category. It serves as a general regulatory announcement, so it fits best under the fallback category Regulatory Filings (RNS).
2026-04-24 English
Inify Laboratories har tecknat avtal med Region Jämtland Härjedalen för prostatacancerdiagnostik - Attachment: Inify_Avtal_signerat_med_Region_Jamtland_Harjedalen.pdf
Regulatory Filings Classification · 30% confidence The document is a corporate press release announcing Inify Laboratories’ new agreement with Region Jämtland Härjedalen for prostate cancer diagnostics. It contains no financial results, no board or management changes, no share issuance or M&A activity, and is not a transcript or detailed report. It is a general regulatory announcement (press release under MAR). Therefore it best fits the fallback category: Regulatory Filings (RNS).
2026-04-24 Swedish

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.